Cambrex opening new high-potency API facility in U.S.

Cambrex is set to open a new HPAPI facility at its Charles City, Iowa site. (Cambrex)

High-potency drugs remain in high demand, and Cambrex continues to build new facilities to capture that market. Its facility in Iowa will be ready to churn out active pharmaceutical ingredients beginning in May.

The East Rutherford, New Jersey-based small molecule specialist has completed a new $24 million facility in Charles City, Iowa. The 6,000-square-foot, four-reactor facility is currently being validated, the company said Wednesday.

With reactors that range from 200 to 1,000 gallons in capacity, the facility can handle projects up to 300 kg and support all phases of development, Cambrex said. A spokesman said in an email that Cambrex will add a dozen new jobs. 

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

RELATED: Cambrex adds Avista Pharma to the fold in $250M deal

“We have seen an increased number of molecules in the clinical pipeline being designated as potent and highly potent, so having the flexibility within our manufacturing network to scale up with existing customers as projects progress, as well as accommodate new projects, is crucial to meet those market needs,” John Andrews, VP of operations and director for the Charles City site, said in a statement.

Cambrex manufactures a range of APIs and pharmaceutical intermediates including highly potent molecules and controlled substances at the Iowa site, where it employs more than 370 people.

Other companies are scaling up their high-potency API capabilities as well. A year ago, South Africa’s Aspen Pharmacare opened an $80 million facility at its site in Port Elizabeth.

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.